IRCT20240302061146N1 IRCT 2024-04-05 Mashhad University of Medical Sciences Octreotide and indomethacin in the prevention of post ERCP pancreatitis Investigating the effect of adding octreotide to indomethacin compared to indomethacin alone in preventing pancreatitis after ERCP in high-risk patients: a randomized clinical trial 2024-04-20 anticipated 88 Complete https://irct.ir/trial/75866 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Allocation will be conducted in a 1:1 ratio using blocks of size 4 (AABB, ABAB, ABBA, BAAB, BABA, BBAA). Each generated block will be assigned a specific number. A random order of the blocks will be created by utilizing an online randomization tool such as randomizer.org (https://www.randomizer.org). Allocation of patients to study groups will be done using sealed envelopes. 2 Acute pancreatitis following endoscopic retrograde cholangiopancreatography. Intervention 1: Intervention group (Indomethacin + octreotide group): Octreotide will be infused 100 micrograms intravenously during ERCP as a state and then 50 micrograms intravenously every six hours for 48 hours. Indomethacin 100 mg will be administered rectally at the same time as ERCP. Intervention 2: Control group (Indomethacin alone group): Indomethacin 100 mg will be administered rectally at the same time as ERCP. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information